These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 15485168)

  • 21. Risk factors associated with nonalcoholic fatty liver disease and its relationship with the hepatic histological changes.
    Rodríguez-Hernández H; Gonzalez JL; Márquez-Ramirez MD; Flores-Hernandez M; Rodríguez-Morán M; Guerrero-Romero F
    Eur J Gastroenterol Hepatol; 2008 May; 20(5):399-403. PubMed ID: 18403941
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Liver enzymes and histology in obese patients with obstructive sleep apnea.
    Kallwitz ER; Herdegen J; Madura J; Jakate S; Cotler SJ
    J Clin Gastroenterol; 2007; 41(10):918-21. PubMed ID: 18090161
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies.
    Adams LA; Sanderson S; Lindor KD; Angulo P
    J Hepatol; 2005 Jan; 42(1):132-8. PubMed ID: 15629518
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chronic effects of celecoxib, a cyclooxygenase-2 inhibitor, cause enhanced alcohol-induced liver steatosis in rats.
    Bykov IL; Palmen M; Rainsford KD; Lindros KO
    Inflammopharmacology; 2006 Mar; 14(1-2):36-41. PubMed ID: 16835711
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Aspartate aminotransferase (AST) more than alanine aminotransferase (ALT) levels predict the progression of liver fibrosis in chronic HCV infection].
    Stránský J; Ryzlová M; Striteský J; Horák J
    Vnitr Lek; 2002 Oct; 48(10):924-8. PubMed ID: 16737138
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Beneficial effects of pentoxifylline on hepatic steatosis, fibrosis and necroinflammation in patients with non-alcoholic steatohepatitis.
    Satapathy SK; Sakhuja P; Malhotra V; Sharma BC; Sarin SK
    J Gastroenterol Hepatol; 2007 May; 22(5):634-8. PubMed ID: 17444848
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hepatic steatosis in chronic hepatitis B patients is associated with metabolic factors more than viral factors.
    Peng D; Han Y; Ding H; Wei L
    J Gastroenterol Hepatol; 2008 Jul; 23(7 Pt 1):1082-8. PubMed ID: 18707599
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Expanding postmortem donor pool using steatotic liver grafts: a new look.
    Noujaim HM; de Ville de Goyet J; Montero EF; Ribeiro CM; Capellozzi VL; Crescentini F; Casagrande M; Santos RG; Curvello L; de Miranda MP; Genzini T
    Transplantation; 2009 Mar; 87(6):919-25. PubMed ID: 19300197
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nonalcoholic fatty liver disease.
    Bayard M; Holt J; Boroughs E
    Am Fam Physician; 2006 Jun; 73(11):1961-8. PubMed ID: 16770927
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Spectrum of NAFLD and diagnostic implications of the proposed new normal range for serum ALT in obese women.
    Prati D; Colli A; Conte D; Colombo M
    Hepatology; 2005 Dec; 42(6):1460-1; author reply 1461. PubMed ID: 16317678
    [No Abstract]   [Full Text] [Related]  

  • 31. [Relationship between morphological diagnosis of NASH (non-alcoholic steatohepatitis) and liver function tests in a group of patients with morbid obesity].
    Chavarría-Arciniega S; López-Alvarenga JC; Uribe-Uribe NO; Herrera-Hernández M; González-Barranco J
    Rev Invest Clin; 2005; 57(4):505-12. PubMed ID: 16315634
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Metabolic and histological features of non-alcoholic fatty liver disease patients with different serum alanine aminotransferase levels.
    Wong VW; Wong GL; Tsang SW; Hui AY; Chan AW; Choi PC; Chim AM; Chu S; Chan FK; Sung JJ; Chan HL
    Aliment Pharmacol Ther; 2009 Feb; 29(4):387-96. PubMed ID: 19035982
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Spectrum of histological features in non-alcoholic fatty liver disease.
    Vasdev N; Kakati AG; Saigal S; Nayak NC
    Natl Med J India; 2007; 20(6):282-7. PubMed ID: 18335793
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Pathogenesis, clinical aspects and biochemistry of fatty liver].
    Müting D; Fischer R; Korn U; Reikowski J
    Dtsch Med Wochenschr; 1973 Apr; 98(14):733-7. PubMed ID: 4266619
    [No Abstract]   [Full Text] [Related]  

  • 35. Fibrosis progression in initially mild chronic hepatitis C.
    Boccato S; Pistis R; Noventa F; Guido M; Benvegnù L; Alberti A
    J Viral Hepat; 2006 May; 13(5):297-302. PubMed ID: 16637859
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Nonalcoholic steatohepatitis: a clinicopathological analysis of liver biopsy in 32 cases].
    Meng JR; Zheng RD; Zhang MF; Guo YH; Lin MZ; Dai TJ
    Nan Fang Yi Ke Da Xue Xue Bao; 2006 Mar; 26(3):339-41. PubMed ID: 16546742
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Liver enzymes, fatty liver and type 2 diabetes.
    Neely D
    Ann Clin Biochem; 2005 May; 42(Pt 3):167-9. PubMed ID: 15949150
    [No Abstract]   [Full Text] [Related]  

  • 38. Optimal cut-off value of alanine aminotransferase level to precisely estimate the presence of fatty liver in patients with poorly controlled type 2 diabetes.
    Tanabe A; Tatsumi F; Okauchi S; Yabe H; Tsuda T; Okutani K; Yamashita K; Nakashima K; Kaku K; Kaneto H
    J Diabetes Investig; 2016 Jul; 7(4):645-6. PubMed ID: 27373695
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The elusiveness of "normal" ALT in fatty liver.
    Ratziu V; Imbert-Bismut F; Messous D; Poynard T
    Hepatology; 2004 Apr; 39(4):1172; author reply 1173. PubMed ID: 15057921
    [No Abstract]   [Full Text] [Related]  

  • 40. [Diagnosis and prognosis of fatty liver].
    Wittman I; Trebitsch M
    Wien Z Inn Med; 1967; 48(5):203-7. PubMed ID: 5620281
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.